|
1
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kahlert UD, Nikkhah G and Maciaczyk J:
Epithelial-to-mesenchymal (−like) transition as a relevant
molecular event in malignant gliomas. Cancer Lett. 331:131–138.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Phillips HS, Kharbanda S, Chen R, Forrest
WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et
al: Molecular subclasses of high-grade glioma predict prognosis,
delineate a pattern of disease progression, and resemble stages in
neurogenesis. Cancer Cell. 9:157–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Verhaak RGW, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Cancer Genome Atlas Research Network: Integrated genomic analysis
identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zarkoob H, Taube JH, Singh SK, Mani SA and
Kohandel M: Investigating the link between molecular subtypes of
glioblastoma, epithelial-mesenchymal transition, and CD133 cell
surface protein. PLoS One. 8:e641692013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bhat KPL, Balasubramaniyan V, Vaillant B,
Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L,
James JD, Goodman LD, et al: Mesenchymal differentiation mediated
by NF-κB promotes radiation resistance in glioblastoma. Cancer
Cell. 24:331–346. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD
and Hu SJ: Targeting role of glioma stem cells for glioblastoma
multiforme. Curr Med Chem. 20:1974–1984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murat A, Migliavacca E, Gorlia T, Lambiv
WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven
MC, et al: Stem cell-related self-renewal signature and high
epidermal growth factor receptor expression associated with
resistance to concomitant chemoradiotherapy in glioblastoma. J Clin
Oncol. 26:3015–3024. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kleihues P and Cavenee WK: Pathology and
genetics of tumors of the nervous system. In: World Health
Organization Classification of Tumours. Pathology and Genetics of
Head and Neck Tumours (Lyon, France). IARC Press. 9–15. 2000.
|
|
13
|
Kahlert UD, Maciaczyk D, Doostkam S, Orr
BA, Simons B, Bogiel T, Reithmeier T, Prinz M, Schubert J,
Niedermann G, et al: Activation of canonical WNT/β-catenin
signaling enhances in vitro motility of glioblastoma cells by
activation of ZEB1 and other activators of
epithelial-to-mesenchymal transition. Cancer Lett. 325:42–53. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brabletz T: To differentiate or not -
routes towards metastasis. Nat Rev Cancer. 12:425–436. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baysan M, Woolard K, Bozdag S, Riddick G,
Kotliarova S, Cam MC, Belova GI, Ahn S, Zhang W, Song H, et al:
Micro-environment causes reversible changes in DNA methylation and
mRNA expression profiles in patient-derived glioma stem cells. PLoS
One. 9:e940452014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Heddleston JM, Li Z, McLendon RE,
Hjelmeland AB and Rich JN: The hypoxic microenvironment maintains
glioblastoma stem cells and promotes reprogramming towards a cancer
stem cell phenotype. Cell Cycle. 8:3274–3284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cooper LA, Gutman DA, Chisolm C, Appin C,
Kong J, Rong Y, Kurc T, Van Meir EG, Saltz JH, Moreno CS and Brat
DJ: The tumor microenvironment strongly impacts master
transcriptional regulators and gene expression class of
glioblastoma. Am J Pathol. 180:2108–2119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bar EE, Lin A, Mahairaki V, Matsui W and
Eberhart CG: Hypoxia increases the expression of stem-cell markers
and promotes clonogenicity in glioblastoma neurospheres. Am J
Pathol. 177:1491–1502. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Evans SM, Judy KD, Dunphy I, Jenkins WT,
Hwang WT, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM,
et al: Hypoxia is important in the biology and aggression of human
glial brain tumors. Clin Cancer Res. 10:8177–8184. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schonberg DL, Lubelski D, Miller TE and
Rich JN: Brain tumor stem cells: Molecular characteristics and
their impact on therapy. Mol Aspects Med. 39:82–101. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Piao Y, Liang J, Holmes L, Zurita AJ,
Henry V, Heymach JV and de Groot JF: Glioblastoma resistance to
anti-VEGF therapy is associated with myeloid cell infiltration,
stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol.
14:1379–1392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mahabir R, Tanino M, Elmansuri A, Wang L,
Kimura T, Itoh T, Ohba Y, Nishihara H, Shirato H, Tsuda M and
Tanaka S: Sustained elevation of Snail promotes glial-mesenchymal
transition after irradiation in malignant glioma. Neuro Oncol.
16:671–685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim YH, Yoo KC, Cui YH, Uddin N, Lim EJ,
Kim MJ, Nam SY, Kim IG, Suh Y and Lee SJ: Radiation promotes
malignant progression of glioma cells through HIF-1alpha
stabilization. Cancer Lett. 354:132–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Knecht AK and Bronner-Fraser M: Induction
of the neural crest: A multigene process. Nat Rev Genet. 3:453–461.
2002.PubMed/NCBI
|
|
25
|
Zeisberg M, Hanai J, Sugimoto H, Uddin N,
Lim EJ, Kim MJ, Nam SY, Kim IG, Suh Y and Lee SJ: BMP-7 counteracts
TGF-beta-1-induced epithelial-to mesenchymal transition and
reverses chronic renal injury. Nat Med. 9:964–968. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ and
Feng YM: Cancer-associated fibroblasts induce
epithelial-mesenchymal transition of breast cancer cells through
paracrine TGF-β signaling. Br J Cancer. 110:724–732. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bierie B and Moses HL: Tumour
microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer.
Nat Rev Cancer. 6:506–520. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Song J: EMT or apoptosis: A decision for
TGF-beta. Cell Res. 17:289–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bhowmick NA, Zent R, Ghiassi M, McDonnell
M and Moses HL: Integrin beta 1 signaling is necessary for
transforming growth factor-beta activation of p38MAPK and
epithelial plasticity. J Biol Chem. 276:46707–46713. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Charles NA, Holland EC, Gilbertson R,
Glass R and Kettenmann H: The brain tumor microenvironment. Glia.
59:1169–1180. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dumont N, Wilson MB, Crawford YG, Reynolds
PA, Sigaroudinia M and Tlsty TD: Sustained induction of epithelial
to mesenchymal transition activates DNA methylation of genes
silenced in basal-like breast cancers. Proc Natl Acad Sci USA.
105:14867–14872. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirohashi S: Inactivation of the
E-cadherin-mediated cell adhesion system in human cancers. Am J
Pathol. 153:333–339. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Birchmeier W and Behrens J: Cadherin
expression in carcinomas: Role in the formation of cell junctions
and the prevention of invasiveness. Biochim Biophys Acta.
1198:11–26. 1994.PubMed/NCBI
|
|
34
|
Ye XZ, Xu SL, Xin YH, Yu SC, Ping YF, Chen
L, Xiao HL, Wang B, Yi L, Wang QL, et al: Tumor-associated
microglia/macrophages enhance the invasion of glioma stem-like
cells via TGF-β1 signaling pathway. J Immunol. 189:444–453. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jensen RL: Brain tumor hypoxia:
Tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a
therapeutic target. J Neurooncol. 92:317–335. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iwadate Y, Sakaida T, Hiwasa T, Nagai Y,
Ishikura H, Takiguchi M and Yamaura A: Molecular classification and
survival prediction in human gliomas based on proteome analysis.
Cancer Res. 64:2496–2501. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Castanon L and Baylies MK: A Twist in
fate: Evolutionary comparison of Twist structure and function.
Gene. 287:11–22. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang MH, Wu MZ, Chiou SH, Chen PM, Chang
SY, Liu CJ, Teng SC and Wu KJ: Direct regulation of TWIST by
HIF-1alpha promotes metastasis. Nat Cell Biol. 10:295–305. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elias MC, Tozer KR, Silber JR, Mikheeva S,
Deng M, Morrison RS, Manning TC, Silbergeld DL, Glackin CA, Reh TA
and Rostomily RC: Twist is expressed in human gliomas and promotes
invasion. Neoplasia. 7:824–837. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mikheeva SA, Mikheev AM, Petit A, Beyer R,
Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H,
González-Herrero I, et al: TWIST1 promotes invasion through
mesenchymal change in human glioblastoma. Mol Cancer. 9:1942010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nagaishi M, Paulus W, Brokinkel B, Vital
A, Tanaka Y, Nakazato Y, Giangaspero F and Ohgaki H:
Transcriptional factors for epithelial-mesenchymal transition are
associated with mesenchymal differentiation in gliosarcoma. Brain
Pathol. 22:670–676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Boutet A, De Frutos CA, Maxwell PH, Mayol
MJ, Romero J and Nieto MA: Snail activation disrupts tissue
homeostasis and induces fibrosis in the adult kidney. EMBO J.
25:5603–5613. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng WY, Kandel JJ, Yamashiro DJ, Canoll
P and Anastassiou D: A multi-cancer mesenchymal transition gene
expression signature is associated with prolonged time to
recurrence in glioblastoma. PLoS One. 7:e347052012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang HW, Menon LG, Black PM, Carroll RS
and Johnson MD: SNAI2/Slug promotes growth and invasion in human
gliomas. BMC Cancer. 10:3012010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xie YK, Huo SF, Zhang G, Zhang F, Lian ZP,
Tang XL and Jin C: CDA-2 induces cell differentiation through
suppressing Twist/SLUG signaling via miR-124 in glioma. J
Neurooncol. 110:179–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang Q, Li X, Zhu Y and Yang P:
MicroRNA-16 suppresses epithelial-mesenchymal transition-related
gene expression in human glioma. Mol Med Rep. 10:3310–3314.
2014.PubMed/NCBI
|
|
47
|
Sánchez-Tilló E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Qi S, Song Y, Peng Y, Wang H, Long H, Yu
X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple
pathways regulating cell proliferation, migration, invasion, and
apoptosis in glioma. PLoS One. 7:e388422012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Edwards LA, Woolard K, Son MJ, Li A, Lee
J, Ene C, Mantey SA, Maric D, Song H, Belova G, et al: Effect of
brain- and tumor-derived connective tissue growth factor on glioma
invasion. J Natl Cancer Inst. 103:1162–1178. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kim K, Lu Z and Hay ED: Direct evidence
for a role of beta-catenin/LEF-1 signaling pathway in induction of
EMT. Cell Biol Int. 26:463–476. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Paul I, Bhattacharya S, Chatterjee A and
Ghosh MK: Current understanding on EGFR and Wnt/β-catenin signaling
in glioma and their possible crosstalk. Genes Cancer. 4:427–446.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sandberg CJ, Altschuler G, Jeong J,
Strømme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost
O, Helseth E, Vik-Mo EO, et al: Comparison of glioma stem cells to
neural stem cells from the adult human brain identifies
dysregulated Wnt- signaling and a fingerprint associated with
clinical outcome. Exp Cell Res. 319:2230–2243. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Clevers H, Loh KM and Nusse R: Stem cell
signaling. An integral program for tissue renewal and regeneration:
Wnt signaling and stem cell control. Science. 346:12480122014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gong A and Huang S: FoxM1 and
Wnt/β-catenin signaling in glioma stem cells. Cancer Res.
72:5658–5662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jin X, Jeon HY, Joo KM, Kim JK, Jin J, Kim
SH, Kang BG, Beck S, Lee SJ, Kim JK, et al: Frizzled 4 regulates
stemness and invasiveness of migrating glioma cells established by
serial intracranial transplantation. Cancer Res. 71:3066–3075.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Brabletz S, Bajdak K, Meidhof S, Burk U,
Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J
and Brabletz T: The ZEB1/miR-200 feedback loop controls NOTCH
signalling in cancer cells. EMBO J. 30:770–782. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fan X, Khaki L, Zhu TS, Soules ME, Talsma
CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, et al: NOTCH pathway
blockade depletes CD133-positive glioblastoma cells and inhibits
growth of tumor neurospheres and xenografts. Stem Cells. 28:5–16.
2010.PubMed/NCBI
|
|
59
|
Hu YY, Fu LA, Li SZ, Chen Y, Li JC, Han J,
Liang L, Li L, Ji CC, Zheng MH and Han H: Hif-1α and Hif-2α
differentially regulate NOTCH signaling through competitive
interaction with the intracellular domain of NOTCH receptors in
glioma stem cells. Cancer Lett. 349:67–76. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kristoffersen K, Villingshøj M, Poulsen HS
and Stockhausen MT: Level of NOTCH activation determines the effect
on growth and stem cell-like features in glioblastoma multiforme
neurosphere cultures. Cancer Biol Ther. 14:625–637. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Stockhausen MT, Kristoffersen K and
Poulsen HS: NOTCH signaling and brain tumors. Adv Exp Med Biol.
727:289–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Anido J, Sáez-Borderías A, Gonzàlez-Juncà
A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I,
Martínez-Sáez E, Prudkin L, et al: TGF-β receptor inhibitor target
CD44(high)/Id1(high) glioma-initiating cell population in human
glioblastoma. Cancer Cell. 18:655–668. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kaaijk P, Troost D, Morsink F, Keehnen RM,
Leenstra S, Bosch DA and Pals ST: Expression of CD44 splice
variants in human primary brain tumors. J Neurooncol. 26:185–190.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Merzak A, Koocheckpour S and Pilkington
GJ: CD44 mediates human glioma cell adhesion and invasion in vitro.
Cancer Res. 54:3988–3992. 1994.PubMed/NCBI
|
|
65
|
Xu Y, Stamenkovic I and Yu Q: CD44
attenuates activation of the hippo signaling pathway and is a prime
therapeutic target for glioblastoma. Cancer Res. 70:2455–2464.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wei KC, Huang CY, Chen PY, Feng LY, Wu
TWE, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, et al: Evaluation
of the prognostic value of CD44 in glioblastoma multiforme.
Anticancer Res. 30:253–259. 2010.PubMed/NCBI
|
|
67
|
Katsushima K and Kondo Y: Non-coding RNAs
as epigenetic regulator of glioma stem-like cell differentiation.
Front Genet. 5:142014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Montagner S, Dehó L and Monticelli S:
MicroRNAs in hematopoietic development. BMC Immunol. 15:142014.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Piubelli C, Meraviglia V, Pompilio G,
D'Alessandra Y, Colombo GI and Rossini A: MicroRNAs and cardiac
cell fate. Cells. 3:802–823. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Godlewski J, Newton HB, Chiocca EA and
Lawler SE: MicroRNAs and glioblastoma; the stem cell connection.
Cell Death Differ. 17:221–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Møller HG, Rasmussen AP, Andersen HH,
Johnsen KB, Henriksen M and Duroux M: A systematic review of
microRNA in glioblastoma multiforme: Micro-modulators in the
mesenchymal mode of migration and invasion. Mol Neurobiol.
47:131–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Bullock MD, Sayan AE, Packham GK and
Mirnezami AH: MicroRNAs: Critical regulators of epithelial to
mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in
cancer progression. Biol Cell. 104:3–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shi Z, Zhang J, Qian X, Han L, Zhang K,
Chen L, Liu J, Ren Y, Yang M, Zhang A, et al: AC1MMYR2, an
inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses
epithelial-mesenchymal transition and suppresses tumor growth and
progression. Cancer Res. 73:5519–5531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Zhang M, Kleber S, Röhrich M, Timke C, Han
N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P, Wirkner U,
et al: Blockade of TGF-β signaling by the TGFβR-I kinase inhibitor
LY2109761 enhances radiation response and prolongs survival in
glioblastoma. Cancer Res. 71:7155–7167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Timke C, Zieher H, Roth A, Hauser K,
Lipson KE, Weber KJ, Debus J, Abdollahi A and Huber PE: Combination
of vascular endothelial growth factor receptor/platelet-derived
growth factor receptor inhibition markedly improves radiation tumor
therapy. Clin Cancer Res. 14:2210–2219. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhou YC, Liu JY, Li J, Zhang J, Xu YQ,
Zhang HW, Qiu LB, Ding GR, Su XM, Mei-Shi and Guo GZ: Ionizing
radiation promotes migration and invasion of cancer cells through
transforming growth factor-beta-mediated epithelial-mesenchymal
transition. Int J Radiat Oncol Biol Phys. 81:1530–1537. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Theys J, Jutten B, Habets R, Paesmans K,
Groot AJ, Lambin P, Wouters BG, Lammering G and Vooijs M:
E-Cadherin loss associated with EMT promotes radioresistance in
human tumor cells. Radiother Oncol. 99:392–397. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Meng J, Li P, Zhang Q, Yang Z and Fu S: A
radiosensitivity gene signature in predicting glioma prognostic via
EMT pathway. Oncotarget. 5:4683–4693. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Piao Y, Liang J, Holmes L, Henry V, Sulman
E and de Groot JF: Acquired resistance to anti-VEGF therapy in
glioblastoma is associated with a mesenchymal transition. Clin
Cancer Res. 19:4392–4403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Jain RK: Normalization of tumor
vasculature: An emerging concept in antiangiogenic therapy.
Science. 307:58–62. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gilbert MR, Dignam JJ, Armstrong TS, Wefel
JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S,
Won M, et al: A randomized trial of bevacizumab for newly diagnosed
glioblastoma. N Engl J Med. 370:699–708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Chinot OL, Wick W, Mason W, Henriksson R,
Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea
D, et al: Bevacizumab plus radiotherapy-temozolomide for newly
diagnosed glioblastoma. N Engl J Med. 370:709–722. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Behnan J, Isakson P, Joel M, Cilio C,
Langmoen IA, Vik-Mo EO and Badn W: Recruited brain tumor-derived
mesenchymal stem cells contribute to brain tumor progression. Stem
Cells. 32:1110–1123. 2014. View Article : Google Scholar : PubMed/NCBI
|
